Drug intelligence / Profile preview

MK-8666

Development stage: Phase 1
Lead developer: Merck
Modality: Small Molecules
Administration: Oral

Overview

MK-8666 is an investigational small molecule drug developed by Merck & Co. It acts as a partial agonist of the G-protein coupled receptor 40 (GPR40), also known as free fatty acid receptor 1 (FFAR1). Activation of FFAR1 enhances insulin secretion in a glucose-dependent manner, making it a potential therapeutic agent for type 2 diabetes mellitus. The drug was evaluated in phase I clinical trials for safety, tolerability, pharmacodynamics, and pharmacokinetics in patients with type 2 diabetes mellitus. No further development has been reported beyond phase I[1][2][3][5].

Other names: 1544739-75-4UNII-11612L5SPIUNII11612L5SPIUNII 11612L5SPI

Targets

FFAR1 (Free fatty acid receptor 1)

Beyond the preview

Go deeper on MK-8666.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MK-8666.

Explore the full profile